About Human Biosciences India Limited
Data last updated: 13 February 2026
Human Biosciences India Limited is a public limited company based in Delhi, Delhi, India, a subsidiary of Human Bioscience Inc Us. It specialises in medical consumables and supplies, a part of the broader healthcare sector. Incorporated on 11 September 2000, the company has been in operation for over 26 years.
Registered with ROC Delhi under CIN U24239DL2000PTC107655.
Capital: an authorised share capital of ₹30 Cr and a paid-up capital of ₹29.12 Cr. Formerly known as Envy International Private Limited and Human Biosciences India Private Limited. It is led by directors including Kolluru Venkata Surya Prakash and Manoj Kumar Jain.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Desk No 12 Cw – 59 First Floor, Sanjay Gandhi Transport Nagar, Delhi, Delhi, India – 110042.
As per the financials filed for FY 2025, the company reported a revenue of ₹3.21 Cr, a decline of 30% compared to the previous year.
The company has a workforce of approximately 1 employees as per the latest available data. It operates as a subsidiary of Human Bioscience Inc Us.
The company is associated with 1 brand - Human Biosciences. As per MCA filings, the company has satisfied charges of ₹141.86 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website humanbiosciences.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressDesk No 12 Cw – 59 First Floor, Sanjay Gandhi Transport Nagar, Delhi, Delhi, India – 110042
-
IndustryHealthcare, Medical Consumables & Supplies
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Human Biosciences India Limited
Human Biosciences India Limited has undergone 2 name changes throughout its history. The company was previously known as Envy International Private Limited, and Human Biosciences India Private Limited. The current legal name is Human Biosciences India Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Human Biosciences India Limited | Current |
| Envy International Private Limited | Previous |
| Human Biosciences India Private Limited | Previous |
CIN History of Human Biosciences India Limited
Human Biosciences India Limited has one previous CIN (Corporate Identification Number): U24239DL2000PTC107655. The current CIN is U24239DL2000PLC107655, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239DL2000PLC107655 | Current |
| U24239DL2000PTC107655 | Previous |
Associated Brands with Human Biosciences India Limited
Human Biosciences India Limited operates one associated brand: Human BioSciences. These brands represent Human Biosciences India Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Develops and manufactures medical-grade wound care solutions using collagen technology. | humanbiosciences.com |
Competitors & Alternatives of Human Biosciences India Limited
Brands and companies operating in the same space as Human Biosciences India Limited include Ilya Pharma, QBiotics, Tempo Therapeutics and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Ilya Pharma
|
Biological drugs for skin and mucosa wound treatment are developed. | Uppsala, Sweden, Sweden | 2016 |
QBiotics
|
Small molecules from plant extracts are developed for medical applications. | Brisbane, Australia, Australia | 2000 |
Tempo Therapeutics
|
Regenerative biomaterials for wounds are developed using particle technology. | San Diego, United States, United States | 2014 |
Resolution Therapeutics
|
Macrophage cell therapies are developed for inflammatory and liver diseases. | Edinburgh, United Kingdom, United Kingdom | 2017 |
MediWound
|
Enzymatic therapies for tissue repair and regeneration are developed. | Yavne, Israel, Israel | 2001 |
Nuo Therapeutics
|
Regenerative therapies for wound care and ulcers are developed. | Gaithersburg, United States, United States | 2001 |
ProFibrix
|
Powdered fibrin sealant for surgical bleeding | Leiden, Netherlands, Netherlands | 2004 |
Solsys Medical
|
Human skin allografts and dressings for wound care are supplied. | Norfolk, United States, United States | 1999 |
Claris Bio
|
Topical formulations for corneal wounds, ulcers, and scars are developed. | Jersey City, United States, United States | 2018 |
Mosaic Biosciences
|
Synthetic materials are developed for native tissue regeneration support. | Boulder, United States, United States | 2009 |
Business Activity of Human Biosciences India Limited
Human Biosciences India Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Board of Directors of Human Biosciences India Limited
Human Biosciences India Limited is currently managed by 3 directors, with 11 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Kolluru Venkata Surya Prakash
Also directs:
Meher Infosolutions Private Limited
|
Director | 13 Oct 2008 | 17 Years 8 Months | Current |
| Manoj Kumar Jain | Managing Director | 05 Oct 2009 | 16 Years 9 Months | Current |
| Ashok Kantilal Shah | Director | 23 Mar 2013 | 13 Years 3 Months | Current |
Financials of Human Biosciences India Limited FY 2025 filings available
Human Biosciences India Limited reported revenue of ₹3.21 Cr (down 30% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Human Biosciences India Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Mar 2013 | Bank of Baroda | ₹6 Cr | Satisfied |
| 26 Jun 2012 | Bank of Baroda | ₹6 Cr | Satisfied |
| 03 Mar 2012 | Bank of Baroda | ₹4.5 Cr | Satisfied |
| 19 Feb 2010 | Bank of Baroda | ₹62.68 Cr | Satisfied |
| 28 Jan 2010 | Bank of Baroda | ₹62.68 Cr | Satisfied |
Total charge records: 5 View all charges
Employees and EPFO Compliance at Human Biosciences India Limited
View historical data on people associated with Human Biosciences India Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Human Biosciences India Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Human Biosciences India Limited
GSTIN & GST Filing Data of Human Biosciences India Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Human Biosciences India Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Human Biosciences India Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Human Biosciences India Limited
MSME Payment Delays by Human Biosciences India Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Human Biosciences India Limited
Subsidiaries & Group Companies of Human Biosciences India Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Human Biosciences India Limited with ownership details.
MCA Filings & Documents of Human Biosciences India Limited
MCA Filings & Documents of Human Biosciences India Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Human Biosciences India Limited
Frequently Asked Questions about Human Biosciences India Limited
Human Biosciences India Limited is an active public limited company in the healthcare sector based in Delhi, Delhi, India. It was incorporated on 11 September 2000 (26+ years old) and is registered under CIN U24239DL2000PLC107655. The company has 1 employees.
Human Biosciences India Limited reported revenue of ₹3.21 Cr for FY 2025 (down 30.00% YoY).
The current directors of Human Biosciences India Limited are:
The primary industry of Human Biosciences India Limited is healthcare. The company specifically operates in medical consumables and supplies. The company is currently active in this sector.
Human Biosciences India Limited can be reached at the registered office: Desk No 12 Cw – 59 First Floor, Sanjay Gandhi Transport Nagar, Delhi, Delhi, India – 110042, or through the website humanbiosciences.com.
The authorised capital is ₹30 Cr, and the paid-up capital is ₹29.12 Cr.